Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2025.04.034 | DOI Listing |
Publication Analysis
Top Keywords
reply tirzepatide
4
tirzepatide obesity-related
4
obesity-related heart
4
heart failure
4
failure preserved
4
preserved weight
4
weight loss
4
loss structural
4
structural adaptations
4
reply
1
Similar Publications
Reply to "Revisiting Tirzepatide's Body Composition Model: Underestimated Fat-Free Mass Loss and Clinical Implications".
Clin Pharmacol Ther
September 2025
Global PKPD & Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Reply: Tirzepatide in Obesity-Related Heart Failure With Preserved EF: Weight Loss and Structural Adaptations.
J Am Coll Cardiol
July 2025
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
N Engl J Med
June 2025
Eli Lilly, Indianapolis.
Tirzepatide for Heart Failure and Obesity. Reply.
N Engl J Med
April 2025
Mayo Clinic, Rochester, MN.
Tirzepatide for Weight Reduction in Chinese Adults With Obesity-Reply.
JAMA
December 2024
Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.